China Approves First-in-Class Monoclonal Antibody for Chronic Hepatitis D Treatment
核心洞察
China's drug regulator granted conditional approval to Huahui Health's Libevitug injection for treating chronic hepatitis D virus infection in adults, addressing a significant treatment gap for one of the most severe forms of viral hepatitis.
The monoclonal antibody demonstrated strong clinical efficacy with a 44.1% combined response rate and 60% virological response rate at 48 weeks by blocking hepatitis B and D viruses from entering liver cells.
The approval targets approximately 12 million people worldwide who are co-infected with both hepatitis B and D viruses, a condition that significantly accelerates liver disease progression and increases cirrhosis and liver cancer risk.
China's drug regulator has granted conditional approval to Huahui Health's Libevitug injection for treating chronic hepatitis D virus infection in adults, marking a significant breakthrough in addressing one of the most severe forms of viral hepatitis. The approval, announced Friday, represents the first treatment option specifically designed to fill a long-standing therapeutic gap for patients with this challenging co-infection.
Novel Mechanism Targets Viral Entry
Libevitug is a monoclonal antibody that works by blocking hepatitis B and D viruses from entering liver cells, specifically targeting the PreS1 domain of the viral envelope. The drug has been approved for patients with or without compensated cirrhosis, expanding treatment options for a broad patient population affected by this severe form of hepatitis.
The hepatitis D virus is classified as a "defective" virus that requires hepatitis B virus to replicate, making chronic HDV infection possible only in HBV carriers. This co-infection significantly accelerates liver disease progression, substantially increasing the risk of cirrhosis and liver cancer compared to hepatitis B infection alone.
Addressing Global Health Burden
The World Health Organization estimates that nearly 5 percent, or approximately 12 million people, of the 254 million individuals living with chronic hepatitis B worldwide are also infected with hepatitis D. This substantial patient population has historically faced limited treatment options, making Libevitug's approval particularly significant for global hepatitis management.
Strong Clinical Trial Results
Clinical trial data demonstrated that Libevitug significantly outperformed a control group across multiple key indicators, including viral response, normalization of liver enzymes, and improvement in liver stiffness. At 48 weeks, the combined response rate reached 44.1 percent, with a virological response rate of 60 percent.
These results were presented at the 2025 annual meeting of the American Association for the Study of Liver Diseases, providing the medical community with comprehensive data on the drug's efficacy profile.
Regulatory Recognition
The drug had previously received breakthrough therapy designation from both China's National Medical Products Administration and the US Food and Drug Administration, according to Huahui Health. This dual recognition underscores the treatment's potential role in improving hepatitis diagnosis and treatment while supporting broader efforts to reduce liver disease and related deaths.
The breakthrough therapy designations highlight the urgent medical need for effective hepatitis D treatments and the significant clinical advancement that Libevitug represents in addressing this challenging co-infection.